DCOY · Decoy Therapeutics Inc.
$4.03
-0.01 (-0.25%)
At close · Jul 29
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. Based on Decoy's expected cash requirements, Decoy believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date.”View the 10-Q filed May 8, 2026
Market Cap
$2.15M
Shares
531,968
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.03
Open$3.97
Day$3.90–4.32
52W$3.57–415.80
Avg vol 30d498K
Short int24K · 4.5% float · 1.0d
Short vol15%
Last earningsAug 15, 2022
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−65%
below
Price vs 50-day avg
−36%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−44%
trailing
6-month return
−47%
trailing
YTD return
−48%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-56% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.51% of float · ▼ -84.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — 13F breadth
Squeeze score
35
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−86%
Y/Y
Free cash flow
$-4.8M
Valuation
P/E 0
in line
Balance sheet
$10.7M
net cash
Quant / Vol
risk profile
Volatility
162%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
21.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−65%
Bearish
Price vs 50-day avg
−36%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-56% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.51% of float · ▼ -84.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $4
Now $4 · 0%
52-wk high $416
vs 200-day avg -65%
vs 50-day avg -36%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DCOY
this stock
Decoy Therapeutics Inc.
|
$2.15M | -48.3% | -100.0% | 0.0 | 4.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DCOY | -18.6% | -44.0% | -46.7% | -44.0% | -48.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -17.6% | -43.9% | -54.1% | -43.2% | -56.9% |